Eli Lilly Hits $1 Trillion Value as Weight-Loss Drug Sales Soar

Eli Lilly reached a $1 trillion market capitalization after its fourth-quarter earnings significantly exceeded expectations due to soaring demand for weight-loss drugs.The pharmaceutical company reported $19.3 billion in revenue and adjusted earnings of $7.54 per share while projecting full-year 2026 sales to reach up to $83 billion.This surge occurred as Danish competitor Novo Nordisk saw its shares plummet by 16% following a downward revision of its own financial forecasts.